Quick access to up-to-date company information.
Boehringer Ingelheim Named One of Science Magazine’s Top Employers for the Twelfth Consecutive Year
Boehringer Ingelheim’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study
Efficacy of Ofev® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
New Real-World Data Show Pradaxa® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment
Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877